Vico Therapeutics

Vico Therapeutics aims to transform neurological treatment through genetic precision.

Vico Therapeutics partners to improve patient and family outcomes through innovative approaches.

Vico Therapeutics develops a pipeline of potential first-in-class therapies for neurological conditions.

VO659 is an antisense oligonucleotide therapy targeting genetic causes of neurodegeneration.

Vico Therapeutics publishes research on polyglutamine disease, focusing on quantifying mutant and wild-type polyQ.

FDA clearance of IND application for VO659 with plans to initiate US-based clinical trial later this year New data highlight […]

VO659 is the only clinical-stage candidate targeting the CAG repeat expansion that causes these diseases VO659 was designed to preferentially reduce mutant HTT

Funding supports ongoing Phase 1/2a clinical trial evaluating VO659 in patients with spinocerebellar ataxia type 3 and type 1 and Huntington's disease Financing

The Leiden office in the Netherlands seeks an HR Officer to manage daily human resources processes.

Vico Therapeutics combines scientific research with compassion to address diseases affecting patients.

Rewriting the Code of Neurological Disease Company About Vico Therapeutics is a neurology genetic medicine company pioneering targeted treatments for devastatin

Partnering with Patients, Caregivers, and Advocates Company Contact BioScience Park BioPartner Building 1 J.H. Oortweg 21 2333 CH Leiden The Netherlands Get in

Pioneering RNA-based science to target the root cause of rare genetic neurological diseases VO659: The first clinical candidate directly targeting the CAG repea